Currently bezafibrate is reported to operate as a pan-agonist of all the three PPAR isoforms and has been effective in reducing insulin resistance, glucose, HbA1c, small dense LDL particles, atherosclerotic plaque regression and improves endothelial function [17]. The gene discussed is PPARA; the disease is Insulin resistance.